Document:

Second Amendment to Employment Agreement for Kerry Wentworth

 EXHIBIT 10.11.2 
 AMENDMENT – NUMBER TWO 
 TO EMPLOYMENT AGREEMENT 

December 15, 2010 
 This Amendment Number Two to the Employment Agreement (the “Employment Agreement”) by and between Antigenics Inc. (the “Company”) and Kerry Wentworth (the “Executive”)
effective as of the 20th day of February, 2007, as amended
by Amendment Number One, effective as of July 2, 2009, amends the Employment Agreement effective as of the date hereof as follows: 
 1.
The second sentence of Section 5(d) is amended to read: 
 “In the event of such termination, the Company shall continue to pay the
Executive her Base Salary, at the rate in effect on the date of termination, until the conclusion of a period of twelve (12) months following the date of termination.” 
 2. The second sentence of Section 5(e) is amended to read: 
 “In the event of
termination in accordance with this Section 5(e), the Company shall continue to pay the Executive her Base Salary, at the rate in effect on the date of termination, until the conclusion of a period of twelve (12) months following the date
of termination.” 
 3. The following is added at the end of Section 5(e): 
 “Notwithstanding anything in this Section 5(e) to the contrary, this Section 5(e) shall only be applicable if the Executive provides notice to the Company of the Compensation Reduction
within than 90 days following the initial existence of the condition claimed by the Executive to be a Compensation Reduction, and the Executive, in fact, terminates employment with the Company within 12 months of the initial existence of such
condition.” 
 4. The following is added at the end of Section 5(g)(ii): 

“Notwithstanding anything in the Agreement to the contrary, in the event any provision contained in this agreement regarding payment
or assistance to the Executive related to the continuation of healthcare coverage for the Executive is determined would cause the Company to violate the anti-discrimination rules of the healthcare reform laws known as the Patient Protection and
Affordable Care Act, such provision shall be a nullity.” 
 5. A new Section 5(j) is added at the end of Section 5, to read:

 “(j) Any amounts required to be paid as a Gross-up Payment shall in all cases be paid by the Company to the Executive at
a time and manner consistent with the provisions of Treasury Regulation Section 1.409A-3(i)(1)(v) (regarding the treatment of certain tax gross-up payments as made pursuant to a specified time or fixed schedule).” 

  
 1 

 6. Section 6(d) is restated in its entirety to read: 

“(d) Any payments to be made to the Executive (or to the Executive’s designated beneficiary or estate) hereunder following the
Executive’s termination of employment, other than payments that are expressly stated as paid in a series of installments, shall be paid in the form of a single lump sum, which lump sum shall be paid to the Executive within 60 days following the
date of the Executive’s termination of employment; provided, however, that the foregoing shall not apply in the event it is determined that any payments to the Executive must be deferred for six months in order to comply with Code
Section 409A(a)(2)(B)(i), as provided in Section 6(e), below; and provided further that any references to “termination of employment” or any other similar phrase in this Agreement shall be interpreted to mean a “separation
from service” as that phrase is used for purposes of Code Section 409A.” 
 7. The following is added at the end of
Section 14(c): 
 “Notwithstanding anything in this Agreement to the contrary, termination of employment by the Executive shall not be
considered to be for “Good Reason” unless (i) the Executive provides notice to the Company of the condition claimed to be “Good Reason” within 90 days following the initial existence of such condition, (ii) the Company
fails to remedy such condition within 30 days following its receipt of such notice from the Executive, and (iii) the Executive, in fact, terminates employment with the Company within 12 months of the initial existence of such condition.”

 IN WITNESS WHEREOF, this Amendment has been executed as a sealed instrument by the Company, by its duly authorized
representative, and by the Executive, as of the 15 day of December, 2010. 
  

							
	THE EXECUTIVE	 		 	ANTIGENICS INC., a Delaware corporation
				
	 /s/ Kerry Wentworth
	 		 	By:	 	 /s/ Garo H. Armen

	Kerry Wentworth	 		 	Name:	 	Garo H. Armen, PhD
		 		 	Title:	 	Chairman and CEO

  
 2Second Amendment to Employment Agreement for Garo Armen

 EXHIBIT 10.12.2 
 SECOND AMENDMENT TO EMPLOYMENT AGREEMENT 
 December 15, 2010

 This Second Amendment to the Employment Agreement by and between Antigenics Inc. (the
“Company”) and Garo Armen (the “Executive”) effective as of the 1st day of December, 2005, as amended by the First Amendment effective as of the
2nd day of July, 2009 (the “Employment
Agreement”) amends the Employment Agreement effective as of the date hereof as follows: 
 1. The second sentence of Section 5(d) is
amended to read: 
 “In the event of such termination, the Company shall continue to pay the Executive his Base Salary, at the rate in
effect on the date of termination, until the conclusion of a period of eighteen (18) months following the date of termination.” 
 2.
The first sentence of the flush language in Section 5(e) following subparagraph (iii) is amended to read: 
 “In the event of
termination in accordance with this Section 5.e, the Company shall continue to pay the Executive his Base Salary, at the rate in effect on the date of termination, until the conclusion of a period of eighteen (18) months following the date
of termination.” 
 3. The following is added at the end of Section 5(e): 
 “Notwithstanding anything in this Section 5(e) to the contrary, this Section 5(e) shall only be applicable if the Executive provides notice to the Company of the condition claimed to
constitute Good Reason within than 90 days following the initial existence of such condition, the Company fails to remedy such condition within 30 days of receipt of such notice, and the Executive, in fact, terminates employment with the Company
within 12 months of the initial existence of such condition.” 
 4. The following is added at the end of Section 5(g)(ii): 

“Notwithstanding anything in the Agreement to the contrary, in the event any provision contained in this agreement regarding payment or assistance
to the Executive related to the continuation of healthcare coverage for the Executive is determined would cause the Company to violate the anti-discrimination rules of the healthcare reform laws known as the Patient Protection and Affordable Care
Act, such provision shall be a nullity.” 
 5. A new Section 5(i) is added at the end of Section 5, to read: 

“(i) Any amounts required to be paid as a Gross-up Payment shall in all cases be paid by the Company to the Executive at a time and
manner consistent with the provisions of Treasury Regulation Section 1.409A-3(i)(1)(v) (regarding the treatment of certain tax gross-up payments as made pursuant to a specified time or fixed schedule).” 

  
 1 

 6. Section 6(d) is restated in its entirety to read: 

“(d) Any payments to be made to the Executive (or to the Executive’s designated beneficiary or estate) hereunder following the
Executive’s termination of employment, other than payments that are expressly stated as paid in a series of installments, shall be paid in the form of a single lump sum, which lump sum shall be paid to the Executive within 60 days following the
date of the Executive’s termination of employment; provided, however, that the foregoing shall not apply in the event it is determined that any payments to the Executive must be deferred for six months in order to comply with Code
Section 409A(a)(2)(B)(i), as provided in Section 6(e), below; and provided further that any references to “termination of employment” or any other similar phrase in this Agreement shall be interpreted to mean a “separation
from service” as that phrase is used for purposes of Code Section 409A.” 
 IN WITNESS WHEREOF, this Amendment
has been executed as a sealed instrument by the Company, by its duly authorized representative, and by the Executive, as of the 15 day of December, 2010. 
  

							
	THE EXECUTIVE	 		 	ANTIGENICS INC., a Delaware corporation
				
	 /s/ Garo Armen
	 		 	By:	 	 /s/ John Cerio

	Garo Armen	 		 	Name:	 	John Cerio
		 		 	Title:	 	Vice President Human Resources

  
 2Second Amendment to Employment Agreement for Karen Valentine

 EXHIBIT 10.20.2 
 AMENDMENT – NUMBER TWO 
 TO EMPLOYMENT AGREEMENT 

December 15, 2010 
 This Amendment Number Two to the Employment Agreement (the “Employment Agreement”) by and between Antigenics Inc. (the “Company”) and Karen Valentine (the “Executive”)
effective as of the 16th day of September, 2008, as
amended by Amendment Number One, effective as of July 2, 2009, amends the Employment Agreement effective as of the date hereof as follows: 

1. The second sentence of Section 5(d) is amended to read: 
 “In the event of such termination, the Company shall continue to pay the Executive her Base Salary, at the rate in effect on the date of termination, until the conclusion of a period of twelve
(12) months following the date of termination.” 
 2. The second sentence of Section 5(e) is amended to read: 

“In the event of termination in accordance with this Section 5(e), the Company shall continue to pay the Executive her Base Salary, at the rate
in effect on the date of termination, until the conclusion of a period of twelve (12) months following the date of termination.” 
 3.
The following is added at the end of Section 5(e): 
 “Notwithstanding anything in this Section 5(e) to the contrary, this
Section 5(e) shall only be applicable if the Executive provides notice to the Company of the Compensation Reduction within than 90 days following the initial existence of the condition claimed by the Executive to be a Compensation Reduction,
and the Executive, in fact, terminates employment with the Company within 12 months of the initial existence of such condition.” 
 4. The
following is added at the end of Section 5(g)(ii): 
 “Notwithstanding anything in the Agreement to the contrary, in
the event any provision contained in this agreement regarding payment or assistance to the Executive related to the continuation of healthcare coverage for the Executive is determined would cause the Company to violate the anti-discrimination rules
of the healthcare reform laws known as the Patient Protection and Affordable Care Act, such provision shall be a nullity.” 
 5. A new
Section 5(j) is added at the end of Section 5, to read: 
 “(j) Any amounts required to be paid as a Gross-up
Payment shall in all cases be paid by the Company to the Executive at a time and manner consistent with the provisions of Treasury Regulation Section 1.409A-3(i)(1)(v) (regarding the treatment of certain tax gross-up payments as made pursuant
to a specified time or fixed schedule).” 

  
 1 

 6. Section 6(d) is restated in its entirety to read: 

“(d) Any payments to be made to the Executive (or to the Executive’s designated beneficiary or estate) hereunder following the
Executive’s termination of employment, other than payments that are expressly stated as paid in a series of installments, shall be paid in the form of a single lump sum, which lump sum shall be paid to the Executive within 60 days following the
date of the Executive’s termination of employment; provided, however, that the foregoing shall not apply in the event it is determined that any payments to the Executive must be deferred for six months in order to comply with Code
Section 409A(a)(2)(B)(i), as provided in Section 6(e), below; and provided further that any references to “termination of employment” or any other similar phrase in this Agreement shall be interpreted to mean a “separation
from service” as that phrase is used for purposes of Code Section 409A.” 
 7. The following is added at the end of
Section 14(c): 
 “Notwithstanding anything in this Agreement to the contrary, termination of employment by the Executive shall not be
considered to be for “Good Reason” unless (i) the Executive provides notice to the Company of the condition claimed to be “Good Reason” within 90 days following the initial existence of such condition, (ii) the Company
fails to remedy such condition within 30 days following its receipt of such notice from the Executive, and (iii) the Executive, in fact, terminates employment with the Company within 12 months of the initial existence of such condition.”

 IN WITNESS WHEREOF, this Amendment has been executed as a sealed instrument by the Company, by its duly authorized
representative, and by the Executive, as of the 15 day of December, 2010. 
  

							
	THE EXECUTIVE	 		 	ANTIGENICS INC., a Delaware corporation
				
	 /s/ Karen Valentine
	 		 	By:	 	 /s/ Garo H. Armen

	Karen Valentine	 		 	Name:	 	Garo H. Armen, PhD
		 		 	Title:	 	Chairman and CEO

  
 2

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00186-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00186-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00186-of-00352.parquet"}]]